Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Slide 88 Global haemophilia market is growing by high-single digit Sales of recombinant coagulation factors RecombinateⓇ/Advate® NovoSevenⓇ Coagil VII® ObizurⓇ1 KogenateⓇ/HelixateⓇ Strategic positioning of Novo Nordisk's haemophilia portfolio Feiba® XynthaⓇ/RefactoⓇ Eloctate® NovoEight® Idelvion® RixubisⓇ Novo Nordisk compound Status Strategic position AlprolixⓇ Benefix® NovoSevenⓇ Launched Maintain market leadership NovoEight® Launched Establish presence in a competitive market place Submitted³ Contribute to market conversion 40 DKK billion 35 30 N8-GP 25 CAGR²: 3% CAGR²: 5% CAGR²: 9% 20 15 10 5 0 2013 2017 rFVIIa 2013 2017 2013 2017 rFVIII rFIX 1 ObizurⓇ only indicated for acquired haemophilia 2 CAGR for 5-year period changing diabetes® Refixia®/ RebinynⓇ Approved 4 Contribute to new treatment paradigm NovoThirteenⓇ Launched Launch first recombinant product 3 Submitted in the USA and the EU in Q1 2018 4 Refixia® is the brand name for N9-GP in the EU, and RebinynⓇ is the brand name in the US novo nordisk

View entire presentation